Anti-cancer characteristics of mevinolin against three different solid tumor cell lines was not solely p53-dependent

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 27, Issue 5, 2012, Pages 673-679

  Mahmoud, Ali Mokhtar ^a   Al Abd, Ahmed M ^b   Lightfoot, David A ^c   El Shemy, Hany A ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b NATIONAL RESEARCH CENTRE   (Egypt)

^c SOUTHERN ILLINOIS UNIVERSITY   (United States)

Author keywords

Doxorubicin; Mevinolin; Natural products; P53; Solid tumors

Indexed keywords

DOXORUBICIN; MEVINOLIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL DEATH; CELL STRAIN HEPG2; CELL STRAIN MCF 7; DRUG CYTOTOXICITY; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; LIVER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84866136143     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2011.607446     Document Type: Article

References (32)

1. El-Shemy HA, Aboul-Enein AM, Aboul-Enein KM, Fujita K. Willow leaves' extracts contain anti-tumor agents effective against three cell types. Plos one 2007;2:e178.
2. Nassr-Allah AA, Aboul-Enein AM, Aboul-Enein KM, Lightfoot DA, Cocchetto A., El-Shemy HA. Anti-cancer and anti-oxidant activity of some Egyptian medicinal plants. J Med Plants Res 2009; 3: 799-808.
3. Hong MY, Seeram NP, Zhang Y, Heber D. Anticancer effects of Chinese red yeast rice versus monacolin K alone on colon cancer cells. J Nutr Biochem 2008;19:448-458. (Pubitemid 351783405)
4. Kumari HP, Naidu KA, Vishwanatha S, Narasimhamurthy K, Vijayalakshmi G. Safety evaluation of Monascus purpureus red mould rice in albino rats. Food Chem Toxicol 2009;47: 1739-1746.
5. Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci usa 1990;87:8931-8934. (Pubitemid 120007623)
6. Yang L, Wang Y, Lv TJ, Zhou LQ, Jin J. [Effects of clinically effective dose of lovastatin on prostate cancer PC3 cells]. Beijing Da Xue Xue Bao 2010;42:391-395.
7. Yao CJ, Lai GM, Chan CF, Cheng AL, Yang YY, Chuang SE. Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. Int J Cancer 2006;118:773-779.
8. Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 2010;116:3389-3398.
9. Self TH, Akins D. Dramatic reduction in lipoma associated with statin therapy. J Am Acad Dermatol 2008;58:S30-S31.
10. Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, Fiore LD et al. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 2008;100:134-139. (Pubitemid 351480564)
11. Riganti C, Doublier S, Costamagna C, Aldieri E, Pescarmona G, Ghigo D et al. Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol 2008;74:476-484.
12. Perchellet JP, Perchellet EM, Crow KR, Buszek KR, Brown N, Ellappan S et al. Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins. Int J Mol Med 2009;24:633-643.
13. Klawitter J, Shokati T, Moll V, Christians U, Klawitter J. Effects of lovastatin on breast cancer cells: A proteo-metabonomic study. Breast Cancer Res 2010;12:R16.
14. Sane KM, Mynderse M, Lalonde DT, Dean IS, Wojtkowiak JW, Fouad F et al. A novel geranylgeranyl transferase inhibitor in combination with lovastatin inhibits proliferation and induces autophagy in STS-26T MPNST cells. J Pharmacol Exp Ther 2010;333:23-33.
15. Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C et al. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng 1969;11:1101-1110.
16. Hortobágyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 1997;54 Suppl 4:1-7.
17. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-717. (Pubitemid 10218041)
18. Licata S, Saponiero A, Mordente A, Minotti G. Doxorubicin metabolism and toxicity in human myocardium: Role of cytoplasmic deglycosidation and carbonyl reduction. Chem Res Toxicol 2000;13:414-420. (Pubitemid 30327162)
19. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-1112. (Pubitemid 20213250)
20. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene 1990;93:125-128. (Pubitemid 20353092)
21. Hong MY, Seeram NP, Zhang Y, Heber D. Chinese red yeast rice versus lovastatin effects on prostate cancer cells with and without androgen receptor overexpression. J Med Food 2008;11:657-666.
22. Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C. HMGCoA reductase inhibitor simvastatin overcomes bortezomibinduced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway. Biochem Biophys Res Commun 2008;374:309-314.
23. Mo H, Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood) 2004;229:567-585. (Pubitemid 38878903)
24. Sánchez CA, Rodríguez E, Varela E, Zapata E, Páez A, Massó FA et al. Statin-induced inhibition of MCF-7 breast cancer cell proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated by an enhanced oxidative stress. Cancer Invest 2008;26:698-707.
25. Holstein SA, Knapp HR, Clamon GH, Murry DJ, Hohl RJ. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother Pharmacol 2006;57:155-164. (Pubitemid 41779834)
26. Ahn KS, Sethi G, Aggarwal BB. Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-kappaB pathway. Biochem Pharmacol 2008;75:907-913. (Pubitemid 351174113)
27. Tomiyama N, Matzno S, Kitada C, Nishiguchi E, Okamura N, Matsuyama K. The possibility of simvastatin as a chemotherapeutic agent for all-trans retinoic acid-resistant promyelocytic leukemia. Biol Pharm Bull 2008;31:369-374. (Pubitemid 351442129)
28. Lee SK, Kim YC, Song SB, Kim YS. Stabilization and translocation of p53 to mitochondria is linked to Bax translocation to mitochondria in simvastatin-induced apoptosis. Biochem Biophys Res Commun 2010;391:1592-1597.
29. Milkevitch M, Jeitner TM, Beardsley NJ, Delikatny EJ. Lovastatin enhances phenylbutyrate-induced MR-visible glycerophosphocholine but not apoptosis in DU145 prostate cells. Biochim Biophys Acta 2007;1771:1166-1176. (Pubitemid 47404967)
30. Martirosyan A, Clendening JW, Goard CA, Penn LZ. Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: Potential therapeutic relevance. BMC Cancer 2010;10:103.
31. Park IH, Kim JY, Jung JI, Han JY. Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations. Invest New Drugs 2010;28:791-799.
32. Al-Abd AM, Lee JH, Kim SY, Kun N, Kuh HJ. Novel application of multicellular layers culture for in situ evaluation of cytotoxicity and penetration of paclitaxel. Cancer Sci 2008;99: 423-431.(Pubitemid 351228501)